Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01748864 · ClinicalTrials.gov registry record · Phase 1
Evaluation of the Biodistribution and Safety of 99mTC-Etarfolatide (EC20) in Normal Volunteers
A Phase 1 study of Healthy, sponsored by Endocyte.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
- 2
- Study locations
NCT01748864: Completed Phase 1 study of Healthy, sponsored by Endocyte.
NCT01748864 is a Phase 1 study of Healthy that has completed, run by Endocyte. The registered enrollment target is 23 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01748864, a Phase 1 study of Healthy, has completed, sponsored by Endocyte.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
- 2
- Study locations
Study Summary
A Phase 1, single-center, open-label, single arm, baseline-controlled (for safety) study in normal volunteers. Study will determine biodistribution and excretion of the radioactive drug substance and evaluate the safety and tolerability of 99mTC-Etarfolatide in normal volunteers.
Conditions Studied
Interventions
- DRUG Etarfolatide (EC20)
Study Locations (2)
Florida
- MD Clinical - Hallendale
Indiana
- Horizon Oncology - Lafayette
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2013-04 |
| Est. Completion | 2013-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01748864
The ClinicalTrials.gov registry entry for NCT01748864 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The listed sponsor is Endocyte, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which Etarfolatide (EC20) is the first listed.
NCT01748864 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Indiana.
Frequently Asked Questions
What is clinical trial NCT01748864 about?
NCT01748864 is a clinical study titled "Evaluation of the Biodistribution and Safety of 99mTC-Etarfolatide (EC20) in Normal Volunteers". A Phase 1, single-center, open-label, single arm, baseline-controlled (for safety) study in normal volunteers. Study will determine biodistribution and excretion of the radioactive drug substance and evaluate the safety and tolerability of 99mTC-Etarfolatide in normal volunteers.
What is the current status of trial NCT01748864?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2013-04. Estimated completion is 2013-10.
What conditions does trial NCT01748864 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT01748864?
The interventions under investigation include: Etarfolatide (EC20) (DRUG).
Who is sponsoring clinical trial NCT01748864?
This trial is sponsored by Endocyte, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01748864 being conducted?
This trial has 2 study locations across Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.